<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162006</url>
  </required_header>
  <id_info>
    <org_study_id>160002</org_study_id>
    <nct_id>NCT00162006</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura</brief_title>
  <official_title>Prospective Open-Label Study of the Efficacy and Safety of Immune Globulin Intravenous (Human), 10% TVR Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether Immune Globulin Intravenous (Human), 10% TVR&#xD;
      (Triple Virally Reduced) Solution is an effective and safe treatment in patients with chronic&#xD;
      idiopathic thrombocytopenic purpura.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2003</start_date>
  <completion_date type="Actual">December 3, 2003</completion_date>
  <primary_completion_date type="Actual">December 3, 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects Who Qualify As Treatment Responders</measure>
    <time_frame>Baseline thru Day 15 post treatment</time_frame>
    <description>Subjects who i) had at least one platelet count of ≥50 x 109/L prior to Day 15 and ii) did not require a booster dose prior to Day 15, where Day 15 refers to the fifteenth day after initiation of treatment (Day 1). Otherwise, the subject is a non-responder.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to achieve a platelet count &gt; 50 x 109/L</measure>
    <time_frame>Screening visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve a platelet count &gt; 50 x 109/L</measure>
    <time_frame>Day 1 (initiation of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve a platelet count &gt; 50 x 109/L</measure>
    <time_frame>Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve a platelet count &gt; 50 x 109/L</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve a platelet count &gt; 50 x 109/L</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve a platelet count &gt; 50 x 109/L</measure>
    <time_frame>Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve a platelet count &gt; 50 x 109/L</measure>
    <time_frame>Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve a platelet count &gt; 50 x 109/L</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve a platelet count &gt; 50 x 109/L</measure>
    <time_frame>Day 29 (study termination visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of platelet response</measure>
    <time_frame>Screening visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of platelet response</measure>
    <time_frame>Day 1 (initiation visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of platelet response</measure>
    <time_frame>Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of platelet response</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of platelet response</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of platelet response</measure>
    <time_frame>Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of platelet response</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of platelet response</measure>
    <time_frame>Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of platelet response</measure>
    <time_frame>Day 29 (study termination visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Platelet Count</measure>
    <time_frame>Screening visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Platelet Count</measure>
    <time_frame>Day 1 (initiation visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Platelet Count</measure>
    <time_frame>Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Platelet Count</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Platelet Count</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Platelet Count</measure>
    <time_frame>Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Platelet Count</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Platelet Count</measure>
    <time_frame>Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Platelet Count</measure>
    <time_frame>Day 29 (study termination visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Experiences</measure>
    <time_frame>Throughout the study period of approximately 11 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">28</enrollment>
  <condition>Immune Thrombocytopenic Purpura (ITP)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 and &lt;= 65 years&#xD;
&#xD;
          -  ITP diagnosed at least 6 months prior to study entry by history, physical exam, blood&#xD;
             count and blood smear&#xD;
&#xD;
          -  Baseline platelet count of &lt;= 20 x 10 to the 9th/L determined prior to administration&#xD;
             of the study drug on the day of the first infusion&#xD;
&#xD;
          -  No IVIG treatment for ITP during the two weeks prior to the first infusion of the&#xD;
             study drug&#xD;
&#xD;
          -  For females of child bearing potential, use of adequate birth control measures during&#xD;
             study participation&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serum values of ALT, AST, alkaline phosphatase, and total bilirubin exceeding 2.5&#xD;
             times the upper limit of normal at screening&#xD;
&#xD;
          -  Renal dysfunction defined as serum creatinine greater than or equal to 2 mg/dL at&#xD;
             screening&#xD;
&#xD;
          -  Underlying other autoimmune or lymphoproliferative disorder&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Cardiac insufficiency NYHA III and IV, coronary heart disease (CHD) NYHA III and IV&#xD;
&#xD;
          -  Malignancy or history of malignancy&#xD;
&#xD;
          -  Documented selective IgA deficiency (&lt;= 10 mg/dL)&#xD;
&#xD;
          -  Treatment with another investigational drug in the four weeks prior to study entry or&#xD;
             current treatment with another investigational product&#xD;
&#xD;
          -  History of severe adverse reactions to blood and/or blood products&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Positivity for HIV, or HCV antibodies, or HBsAg&#xD;
&#xD;
          -  History of unresponsiveness to IVIG defined as a peak increment in platelet count &lt;=&#xD;
             20,000/µL coincident with the last IVIG treatment course prior to study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle/Saale</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Györ</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic idiopathic thrombocytopenic purpura</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

